Introduction
This ESHRE guideline on the management of women with premature ovarian insufficiency offers best practice advice on the care of women with premature ovarian insufficiency, both primary and secondary. The patient population comprises women younger than 40 years (which includes Turner Syndrome patients) and women older than 40 years, but with disease onset before 40.
Furthermore, this clinical guideline provides recommendations on the initial assessment and management of women with premature ovarian insufficiency. The initial assessment includes diagnosis, assessment of causation, and basic assessment. The management includes hormonal treatment. Since POI has consequences for health apart from gynaecological issues, these are also described. Consequences of POI and treatment options are included in the following domains: fertility and contraception, bone health, cardiovascular issues, psychosexual function, psychological function, and neurological function.
Other topics discussed are puberty induction, life expectancy, and implications for relatives of women with POI.
This guideline is limited to POI and does not apply to women with low ovarian reserve.
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Methods 1
The guideline was developed according to a well-documented methodology, universal to ESHRE guidelines 2 (Vermeulen, et al., 2014) . 3
In short, 31 key questions were formulated by the guideline group and structured in PICO format (Patient, 4 Intervention, Comparison, Outcome). For each question we searched the databases (PUBMED/MEDLINE , 5
Cochrane library, PsycInfo) from inception to 1 April 2014. The literature searches were limited to studies 6 written in English. Based on the evidence, and after constructing evidence tables and quality assessment, draft 7 recommendations were written by the assigned expert guideline group member. Two 2-day meetings were 8 organised to discuss the evidence and recommendations and to reach consensus on the final formulation of 9 the recommendations. 10
For each recommendation, a grade (A-D) was assigned based on the strength of the supporting evidence 11 (scored from 1++ to 4). In case of absence of evidence, the Guideline Development Group (GDG) could decide 12 on writing good practice points (GPP), based on clinical expertise (see table 1). 13
After finalisation of the guideline draft, an invitation to review was published on the ESHRE website. In 14 addition, an invitation to review was sent to members of the ESHRE special interest group Reproductive 15 Endocrinology (n=6000) and to professional organisations on human reproduction, gynaecology, 16 endocrinology and menopause (n=79). Three hundred ninety-eight comments from 34 reviewers were 17 processed by the methodological expert (NV) and the chair of the GDG (LW) either by adapting the content of 18 the guideline and/or by replying to the reviewer. The review process was summarized in the review report, 19 published on the ESHRE website. 20
The guideline will be considered for update 4 years after publication, with an intermediate assessment 21
of the need for updating 2 years after publication. 22 background information and the supporting evidence for each recommendation can be found in the full 26 version of the guideline available at http://www.eshre.eu/Guidelines-and-Legal/Guidelines 27 What should this condition be called? 28
Primary ovarian insufficiency was first described in 1942 and has, since then, been described with different 29 names and definitions (Albright, et al., 1942) . 30
The term "premature ovarian insufficiency" should be used to describe this condition in research and clinical practice.
GPP 31
How should POI be defined? 32
Premature ovarian insufficiency is a clinical syndrome defined by loss of ovarian activity before the age of 40. 33 POI is characterised by menstrual disturbance (amenorrhea or oligomenorrhea) with raised gonadotropins and 34 low estradiol. 35
What is the prevalence of Premature Ovarian Insufficiency in the general population? 36
The prevalence of POI is approximately 1%. Population characteristics such as ethnicity may affect the 37 prevalence. 38
In view of the long-term health consequences of POI, efforts should be made to reduce the incidence of POI. 39
Modifiable factors may include: (1) gynaecological surgical practice, (2) lifestyle -smoking, (3) modified 40 treatment regimens for malignant and chronic diseases. 41
Autosomal genetic testing is not at present indicated in women with POI, unless there is evidence suggesting a specific mutation (e.g. BPES).
GPP
Screening for 21OH-Ab (or alternatively adrenocortical antibodies (ACA)) should be considered in women with POI of unknown cause or if an immune disorder is suspected.
Refer POI patients with a positive 21OH-Ab/ACA test to an endocrinologist for testing of adrenal function and to rule out Addison's disease (Bakalov, et The possibility of POI being a consequence of a medical or surgical intervention should be discussed with women as part of the consenting process for that treatment.
Although no causal relation has been proved for cigarette smoking and POI, there is a relation to early menopause. Therefore, women who are prone to POI should be advised to stop smoking.
GPP 53
In a significant number of women with POI, the cause is not identified and these women are described as 54 having unexplained or idiopathic POI. 
B
Relatives of women with non-iatrogenic premature ovarian insufficiency who are concerned about their risk for developing POI should be informed that: (1) currently there is no proven predictive test to identify women that will develop POI, unless a mutation known to be related to POI was detected, (2) there are no established POI preventing measures, (3) fertility preservation appears as a promising option, although studies are lacking, and (4) their potential risk of earlier menopause should be taken into account when planning a family.
GPP
59
SEQUELAE OF POI 60
What are the consequences of POI for life expectancy? 61 Untreated POI is associated with reduced life expectancy, largely due to cardiovascular disease Table 1 Interpretation on the grades of recommendations (Vermeulen, et al., 2014) The grades of the recommendations is only based on the strength of the supporting evidence. In formulating strong or weak recommendations, the guideline group took the strength of the supporting evidence into account, but weight it against the benefits and harms, and the preferences of clinicians and patients. 
Grades of recommendations
GPP
Expert opinion
